R-Pharm and Flex Databases to Present Poster on Data Empowered Decision Making at DIA 2014 50th Annual Meeting
Flex Databases, a company specializing in software and consulting services for the healthcare industry, has announced that R-Pharm, a Russian pharmaceutical company, will be presenting a poster on data empowered decision making at DIA 2014 50th Annual Meeting in San Diego, US. The poster has been jointly prepared by R-Pharm and Flex Databases and reflects the experience of implementation of the Flex Databases software platform by R-Pharm.
"There were several questions we needed to solve while scaling our activities and growing the number of projects at R-Pharm", says Mikhail Samsonov, Chief Medical Officer at R-Pharm. "How do we keep track of all our projects, regardless of what stage or functional area they belong to? How do we make sure we maintain the quality of work as new people join? And, most importantly, how do we obtain data for decision making, while not spending unreasonably high amount of time to produce and consolidate reports?
"Flex Databases offered answers to all these questions. We now have a platform which provides a project library and a flexible workflow tool, enabling us to obtain real time project status information and guide activities of our employees at each step. The platform is used to manage and implement projects from a variety of functional areas (Chemistry Manufacturing Control, due diligence, clinical development and operations, regulatory and pharmacovigilance). We are keen to share the knowledge we generated as we believe the industry as a whole could benefit from a move to company-wide platforms, as benefits far outweigh the investment needed. Moreover, growing biotech companies and startups could especially benefit using such approach.”
Related News
-
News Eli Lilly gets ready to launch five new drugs in 2023
Eli Lilly, the American pharmaceutical company (IN, USA) are gearing up for a big year ahead, with hopes to launch five new drugs and capitalise on growing obesity and Alzheimer’s disease markets. -
News Amgen buys Horizon for $27.8 billion in bold step into the rare disease market
Amgen Inc buys pharmaceutical company Horizon Therapeutics in a multibillion-dollar deal, in hopes to capitalise on it's portfolio of drugs in the highly sort after rare disease market. -
News Pharma Supply Chain People Moves
The latest appointments and promotions across the pharmaceutical supply chain. -
News Merck to donate new Ebola vaccine to defend against outbreaks in Uganda
Pharmaceutical giant Merck has announced they will be speeding up the processing of a new vaccine against the latest strain of the Ebola virus, to be donated to a global non-profit organisation for distribution -
News CPHI Podcast Series: Driving innovation with pharmaceutical startups
The latest episode in the CPHI Podcast Series explores how startups are driving innovation by taking high-risk approaches and doing business with greater agility. -
News Greener and efficient processes: Quaternary Ammonium Salts
Quaternary Ammonium Salts play a crucial part in Organic Chemistry processes at many major industries. Discover why.
-
News Biosimilars save patients $11B annually, but barriers to adoption remain in US market
Biosimilars introduce competition into the biologics market, driving down prices and increasing patient access. -
News WHO recommends use of two monoclonal antibody treatments against Ebola
The health body recommended use of treatments by Regeneron and Ridgeback Bio
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance